Baseline Workup for Azathioprine
Before initiating azathioprine, you must obtain TPMT activity testing, complete blood count with differential, liver function tests including transaminases, and renal function tests 1, 2.
Essential Laboratory Tests
TPMT Testing (Mandatory)
- TPMT activity must be checked in all patients prior to receiving azathioprine 1
- This is a Strength A recommendation with level 1+ evidence
- TPMT phenotyping (red blood cell TPMT activity) is the standard approach
- TPMT genotyping is only required for patients with:
- Consider NUDT15 genotyping, particularly in patients of East Asian ancestry (2% have two loss-of-function alleles, 21% have one) 2
Critical caveat: TPMT testing cannot substitute for ongoing CBC monitoring—both are required 2
Baseline Blood Work
The following must be obtained before starting therapy 1:
- Complete blood count (CBC) with differential white cell count
- Liver function tests including transaminases (ALT or AST)
- Renal function tests
Clinical Assessment
Screen for Absolute Contraindications
Evaluate for 1:
- Hypersensitivity to azathioprine or 6-mercaptopurine
- Severe active infections
- Severely impaired hepatic or bone marrow function
- Active pancreatitis
- Known malignancy (relative contraindication—immunosuppression may accelerate disease progression)
- Pregnancy (relative contraindication unless benefits outweigh risks)
- Lactation
Viral Hepatitis Screening
- Check hepatitis B surface antigen (HBsAg) in all patients 1
- Approximately one-third of the world's population has serological evidence of HBV exposure
- HBsAg-positive patients are at risk for disease flare with immunosuppression
- Transaminases alone do not reliably detect all infected individuals 1
Varicella Exposure History
- Document chickenpox/varicella history 3
- Patients without prior chickenpox require immediate attention if exposed during therapy for consideration of zoster immune globulin
Medication Review
Critical Drug Interactions to Identify
Document current use of 2:
- Allopurinol or febuxostat (xanthine oxidase inhibitors): Requires dose reduction of azathioprine to 1/3 to 1/4 usual dose; febuxostat concomitant use not recommended
- Aminosalicylates (sulfasalazine, mesalazine, olsalazine): Inhibit TPMT—use with caution
- Warfarin: Azathioprine may inhibit anticoagulant effect
- ACE inhibitors: Can induce severe leukopenia when combined with azathioprine
- Co-trimoxazole or other myelosuppressive drugs: May cause exaggerated leukopenia
- Ribavirin: Induces severe pancytopenia—avoid combination
Vaccination Status
- Live vaccines are contraindicated 1, 3
- Household members should receive inactive (not live) polio vaccine due to orofecal transmission risk
Special Populations
Renal Impairment
- Use lower end of normal dosage range 1
- Monitor CBC more carefully
- No dose adjustment needed for hemodialysis patients
Hepatic Disease
- Use cautiously with regular monitoring 1
- Reduce dosage if hepatic or hematological toxicity occurs
Patient Counseling Requirements
Before initiating therapy, document discussion of 3:
- Slow onset of action (2-3 months for benefit)
- Need for frequent blood monitoring (weekly initially)
- Signs of bone marrow suppression (unexplained bruising, sore throat, fever)
- Signs of hepatotoxicity (jaundice)
- Hypersensitivity symptoms may mimic flu
- Small increased malignancy risk with long-term use
- Pregnancy avoidance
- Drug interactions
- Varicella exposure precautions
Common pitfall: Failing to check TPMT before starting therapy. Approximately 0.3% of patients have complete TPMT deficiency and will develop life-threatening myelosuppression on standard doses 2, 4. An additional 10% have intermediate activity requiring dose modification 2.